Ingrezza is a medication used to treat tardive dyskinesia and chorea associated with Huntington's disease [1]. It works by selectively inhibiting vesicular monoamine transporter 2 (VMAT2) [2].
How Does Ingrezza Work?
Ingrezza targets VMAT2, a protein that regulates the transport of neurotransmitters like dopamine. By inhibiting VMAT2, Ingrezza reduces the amount of dopamine available in the brain, which is believed to help control involuntary movements associated with tardive dyskinesia and Huntington's disease [2].
What Conditions Does Ingrezza Treat?
Ingrezza is FDA-approved for two main conditions:
* Tardive Dyskinesia: This is a neurological disorder characterized by involuntary, repetitive body movements, often a side effect of long-term use of antipsychotic medications [1].
* Chorea associated with Huntington's Disease: Huntington's disease is a genetic disorder that affects the brain, leading to progressive breakdown of nerve cells. Chorea refers to the involuntary, jerky movements that can occur [1].
When Does Ingrezza's Patent Expire?
The patent landscape for Ingrezza is complex, involving multiple patents related to the drug and its uses. According to DrugPatentWatch.com, the earliest patent expiries for Ingrezza are approaching, with some patents set to expire in the coming years [3]. However, patent challenges and additional patent filings can alter these timelines. For the most current and detailed patent expiration information, DrugPatentWatch.com is a valuable resource [3].
Who Makes Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [1].
What Are the Side Effects of Ingrezza?
Common side effects of Ingrezza include sleepiness, dizziness, dry mouth, constipation, and in some cases, abnormal heart rhythm (QT prolongation) [1]. Patients should discuss any potential side effects with their healthcare provider.
How Does Ingrezza Compare to Other Treatments for Tardive Dyskinesia?
Other medications approved for tardive dyskinesia include Valbenazine (Ingrezza is also approved for chorea associated with Huntington's disease) [1]. These drugs work through different mechanisms, but all aim to reduce involuntary movements. A healthcare provider can determine the most appropriate treatment based on an individual's condition and medical history [1].
What Are the Risks Associated with Ingrezza?
Beyond common side effects, a significant risk associated with Ingrezza is somnolence (sleepiness), which can impair activities requiring mental alertness, such as driving [1]. Patients are advised not to drive or operate heavy machinery until they know how Ingrezza affects them. There is also a risk of QT prolongation, which can lead to serious heart rhythm problems [1].
Sources:
[1] https://www.ingrezza.com/
[2] https://pubmed.ncbi.nlm.nih.gov/27153165/
[3] https://drugpatentwatch.com/